The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Will The Market Value Of The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Increase Between 2026 And 2030?
Over recent years, the market size for the artificial intelligence (AI)-driven rare disease patient finder has expanded significantly. It is projected to increase from $1.62 billion in 2025 to $2.11 billion in 2026, with a compound annual growth rate (CAGR) of 29.9%. Factors contributing to this historical growth include the growing access to electronic health records, the nascent application of data analytics in clinical research, the proliferation of genomic databases, an elevated focus on orphan diseases, and the initial integration of AI into trial recruitment processes.
The artificial intelligence (AI)-driven rare disease patient finder market size is projected to experience substantial growth in the coming years. It is anticipated to expand to $5.95 billion by 2030, achieving a compound annual growth rate (CAGR) of 29.6%. The expansion during this forecast period can be attributed to increased investments in precision medicine research, a rising demand for expedited clinical trial enrollment, the broadening scope of real-world evidence analytics, growing collaboration between healthcare and life sciences firms, and enhanced regulatory support for rare disease innovation. Major developments expected in the forecast period include the increasing adoption of AI-based patient identification algorithms, greater integration of multi-source health data, rising automation of clinical trial recruitment, the expansion of precision patient matching platforms, and an elevated focus on enabling rare disease research.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28129&type=smp
What Influential Factors Are Boosting The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Demand?
The growing embrace of digital health and telemedicine is projected to stimulate the expansion of the artificial intelligence (AI)-driven rare disease patient finder market moving forward. Digital health refers to employing technology, software, and electronic tools to monitor, manage, and improve overall health and wellness. Telemedicine, on the other hand, involves delivering healthcare services remotely through telecommunications technology, such as video calls, mobile applications, and online platforms. This increasing acceptance of digital health and telemedicine is attributed to patients and providers seeking healthcare solutions that are convenient, time-efficient, and easily accessible. The artificial intelligence (AI)-driven rare disease patient finder supports digital health and telemedicine by precisely identifying patients, enabling remote monitoring, facilitating timely virtual consultations, and providing personalized care. For instance, in November 2025, the Organisation for Economic Co operation and Development, a France-based intergovernmental organization, reported that OECD countries have progressed in widening access to EHRs. In 2024, the average availability of online digital health services reached 82%, marking an increase from 79% in 2023 among countries with comparable data. Therefore, the increasing adoption of digital health and telemedicine is driving the growth of the artificial intelligence (AI)-driven rare disease patient finder market.
Which Segment Divisions Form The Structure Of The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market?
The artificial intelligence (AI)-driven rare disease patient finder market covered in this report is segmented –
1) By Component: Software, Services
2) By Deployment Mode: Cloud-Based, On-Premises
3) By Application: Hospitals, Clinics, Research Institutes, Pharmaceutical Companies, Other Applications
4) By End-User: Healthcare Providers, Life Sciences Companies, Payers, Other End-Users
Subsegments:
1) By Software: Electronic Data Capture, Data Management Platform, Analytics And Reporting Tools, Patient Engagement Tools, Clinical Trial Management System
2) By Services: Implementation And Integration, Training And Support, Data Hosting And Security, Consulting Services, Maintenance And Upgrades
What Trends Are Influencing The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market?
Companies operating significantly within the AI-driven rare disease patient finder market are concentrating on developing technological advancements, such as precision patient recruitment solutions. This focus aims to improve the accuracy, speed, and efficiency of identifying suitable patients for rare disease clinical trials, while also reducing recruitment timelines and enhancing trial success rates. A precision patient recruitment solution represents a technology-driven method that employs advanced algorithms and real-world data to precisely identify and engage patients who fulfill specific clinical trial eligibility criteria. For instance, in April 2024, Citeline, a US-based company focused on business intelligence and data analytics, launched Citeline PatientMatch. This platform combines advanced algorithms with comprehensive real-world data, including lab results, biomarkers, and electronic medical records from over 400 hospitals and health systems, to assist sponsors and investigators in identifying eligible patients for clinical trials efficiently and promptly, streamlining enrollment, and supporting diverse and complex study protocols across various therapeutic areas.
Who Are The Firms Contributing To The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Ecosystem?
Major companies operating in the artificial intelligence (AI)-driven rare disease patient finder market are UnitedHealth Group Incorporated, Dassault Systèmes SE, GeneDx Holdings Corp., HealthVerity Inc., ConcertAI Inc., Komodo Health Inc., Unlearn.AI Inc., Antidote Technologies Inc., Healx Ltd., FDNA Inc., Saventic Health Sp. z o.o., Digital Pharma Lab SAS, AnnieGuard Ltd., Rapid Innovation Labs Inc., Sqilline EOOD, TrialX Inc., enGenome Srl, EveryCure Inc., ThinkGenetic Inc., RareSum Inc.
Access The Complete Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Report:
What Is The Largest Regional Market In The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market?
North America was the largest region in the artificial intelligence (AI)-driven rare disease patient finder market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI)-driven rare disease patient finder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=28129&type=smp
Browse Through More Reports Similar to the Global Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market 2026, By The Business Research Company
Ai In Medical Diagnostics Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/ai-in-medical-diagnostics-global-market-report
Artificial Intelligence Ai In Clinical Trials Global Market Report 2026
Artificial Intelligence In Cancer Diagnostics Global Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
